Showing results (131-140 of 297) with videos related to
Sort By:
Pageof 30
Cancer Research|June 19, 2004
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicityM Eileen Dolan, Karla G Newbold, Ramamoorthy Nagasubramanian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2005
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901Walter M Stadler, Gary Rosner, Eric Small, et al.Investigational New Drugs|September 15, 2010
A phase I study of continuous infusion cilengitide in patients with solid tumorsPeter H O'Donnell, Samir D Undevia, Walter M Stadler, et al.NPJ Breast Cancer|March 15, 2022
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savingsPo-Hung Hsieh, Alec J Kacew, Marie Dreyer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2012
Resampling phase III data to assess phase II trial designs and endpointsManish R Sharma, Theodore G Karrison, Yuyan Jin, et al.BMC Health Services Research|January 1, 2013
Unsupported off-label chemotherapy in metastatic colon cancerJonas A de Souza, Blase Polite, Monica Perkins, et al.NPJ Genomic Medicine|November 2, 2021
Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomicsLoren Saulsberry, Keith Danahey, Brittany A Borden, et al.Cancer|June 24, 2014
The development of a financial toxicity patient-reported outcome in cancer: The COST measureJonas A de Souza, Bonnie J Yap, Fay J Hlubocky, et al.Cancer Chemotherapy and Pharmacology|August 24, 2011
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patientsJacqueline Ramírez, Kehua Wu, Linda Janisch, et al.Clinical Pharmacology and Therapeutics|November 13, 2004
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbitalFederico Innocenti, Samir D Undevia, Jacqueline Ramírez, et al.Pageof 30